OSE Pharma Announces Initiation Of Its Pivotal Phase 3 ...
OSE Pharma SA, an immunooncology company developing a T-specific immunotherapy for late-stage cancerpatients, has announced the initiation of its registration clinical trial n...
OSE Pharma SA, an immunooncology company developing a T-specific immunotherapy for late-stage cancerpatients, has announced the initiation of its registration clinical trial n...
This update also covers a warning that combination drugs can cause serious liver injury and approval of new drugs for metastatic non-small-cell lung cancer that has progressed...
http://feedproxy.google.com/~r/AcpInternistContents/~3/qxCK0Ci1EqI/fda.htm
Jan. 4, 2016—Patients younger than 50 diagnosed with non-small cell lung cancer have a higher likelihood of having a targetable ... The post Younger age linked to targetab...
http://www.captodayonline.com/younger-age-linked-targetable-genotypes-nsclc/
Former U.S. Rep. Mike Oxley, who helped write landmark anti-fraud legislation following a wave of corporate scandals that brought down Enron Corp. and WorldCom Inc., died Frid...
http://www.sun-sentinel.com/ct-mike-oxley-dies-20160101-story.html
Transgene SA has announced that the results from the Phase 2b part of the Phase 2b/3 TIME trial with TG4010 immunotherapy in non-small cell lung cancer (NSCLC) have been publi...
Oncogenic mutations in Kirsten rat sarcoma viral oncogene homolog (KRAS) occur in 15%–30% of non-small cell lung cancer (NSCLC). However, despite decades of intensive resear...
http://abbs.oxfordjournals.org/cgi/content/short/48/1/11?rss=1
Merrimack Pharmaceuticals has filed an amendment to its ongoing Phase 2 clinical study of MM-121 (seribantumab) in patients with heregulin-positive non-small cell lung cancer ...
BIO-IT WORLD NEWS BRIEF | Foundation Medicine has signed an agreement with UnitedHealthcare to offer Foundationone, a comprehensive genomic profiling assay for solid tumors, ...
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, has announced that it has initiated a Phase I/II study of its...
Results from a pivotal phase 2/3 trial show more patients with advanced non-small-cell lung cancer could benefit from the FDA-approved immunotherapy drug pembrolizumab.
A Yale-led international study in patients with advanced non-small cell lung (NSCLC) cancer resistant to chemotherapy has found a promising weapon in an immune therapy drug co...
http://medicalxpress.com/news/2015-12-immune-therapy-drug-results-prolonged.html
Patients younger than 50 diagnosed with non-small-cell lung cancer (NSCLC) had a higher likelihood of having a targetable genomic alteration for which therapies exist, accordi...